Skip to main content
About
Management Team
Board of Directors
Scientific Advisory Board
Business Development
Careers
Contact Us
Pipeline
Programs
Sitravatinib (MGCD516)
KRAS G12C Inhibitor (MRTX849)
Posters/Publications
Clinical Trials
Mirati Sponsored Trials
Collaboration Trials
Expanded Access Policy
(Compassionate Use)
Investors
Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Financials & Filings
Corporate Governance
Investor FAQs
IR Contact
Emails Alerts
News Releases
Normal
Press release year list
2019
2018
2017
2016
2015
2014
2013
11/09/2019
Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
11/04/2019
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
10/28/2019
Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
10/23/2019
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
10/17/2019
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
8/15/2019
Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources
8/05/2019
Mirati Therapeutics Reports Second Quarter 2019 Financial Results
7/09/2019
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
7/01/2019
Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors
6/27/2019
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
6/25/2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
6/24/2019
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
5/30/2019
Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference
4/29/2019
Mirati Therapeutics Reports First Quarter 2019 Financial Results
4/01/2019
Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
3/05/2019
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
2/28/2019
Mirati Therapeutics Reports Fourth Quarter Financial Results
2/19/2019
Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors
2/07/2019
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
1/22/2019
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
1/16/2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
1/16/2019
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
1/15/2019
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
1/07/2019
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
1/02/2019
Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference